As a result of increasing concerns over falsified medicines, reimbursement fraud and theft throughout the pharmaceutical supply chain, by 2019 over 55 countries will have introduced serialisation and track and trace regulations. With varying legislation coming into force across the globe, understanding the requirements of the markets you operate in is of paramount importance.
Press & events
Stay updated on our latest news and events.
ABSTRACT: Glioblastoma remains an incurable brain cancer. Drugs developed in the past 20 years have not improved the prognosis for patients, necessitating the development of new treatments. We have previously reported the therapeutic potential of the quinoline methanol Vacquinol-1 (1) that targets glioblastoma cells and induces cell death by catastrophic vacuolization.
The many challenges faced by the pharmaceutical industry throughout the supply chain, including fraud and counterfeit medicines, have led to international serialisation requirements in the U.S and Europe. With this in mind, CDMOs have a lot to consider with the new track and trace regulations.
Abstract: 6H-1,3,4-Thiadiazines are a promising class of non-aromatic heterocycles for the agricultural and pharmaceutical industry. Although known for a long time, they have not received widespread attention, in part due to their cumbersome synthesis.
The risk of failure and cost invovled with developing new pharmaceutical products can be significantly reduced by using existing active ingredients in the development process and choosing the right partner for the development of the specific requirements of microtablets is crucial.